%20(1).png)
Saturn Group
OUR UPCOMING INITIATIVE
"Bridging nuclear science and healthcare to deliver hope where it matters most."
Pioneering the future of precision oncology in India through advanced targeted radionuclide therapy with Iodine-131 and Actinium-225.
OUR VISION
Transforming Cancer Care Through Nuclear Advancement
Saturn Group is embarking on a transformative journey to establish India as a hub for advanced radiopharmaceutical therapies. Our upcoming initiative focuses on the strategic import and distribution of therapeutic radioisotopes that are revolutionising oncology worldwide.
​
Saturn coordinates sourcing, shipment planning, and final delivery through a tightly managed process that accounts for both time sensitivity and material integrity. Each movement is aligned with the operational realities of nuclear medicine, where timing, condition, and continuity are critical.
Where treatment timelines depend on isotope availability, this initiative reduces uncertainty to support continuity in clinical care while enabling the evolution of oncology care.
PROJECT TIMELINE
Our Roadmap
A structured approach to establishing India's premier radiopharmaceutical supply chain.
PHASE 1
In Progress
Licensing and import permit acquisition
PHASE 2
Planned
Establishing supply chain with certified producers
PHASE 3
Planned
Cold chain and handling facility establishment
PHASE 4
Upcoming
Commercial distribution to healthcare partners
Iodine (131)
Established, Targeted, Essential
BETA-EMITTING
I-131 remains one of the most widely used isotopes in therapeutic nuclear medicine, particularly in treatments involving the thyroid.
​
Its effectiveness lies in its ability to localise within thyroid tissue, allowing radiation to be delivered directly to the affected area without broader systemic impact.
​
Iodine-131 has a half-life of approximately 8 days, allowing sufficient time for treatment administration while maintaining effective therapeutic activity.
Clinical Applications
-
Thyroid Cancer Treatment
-
Hyperthyroidism Therapy
-
Thyroid Ablation
-
Differentiated Thyroid Carcinoma
Actinium (225)
Focused Therapy at the Cellular Level
ALPHA-EMITTING
Ac-225 represents a more advanced approach to cancer therapy, used in treatments that operate at a microscopic, highly targeted scale.
​
When attached to specific carrier molecules, it enables radiation to be delivered directly to cancer cells, limiting exposure beyond the intended site.
​
Actinium-225 has a half-life of around 10 days, supporting its use in targeted therapies that require controlled delivery over a defined period.
Clinical Applications
-
Prostate Cancer (PSMA)
-
Neuroendocrine Tumors
-
Leukemia Treatment
-
Advanced Metastatic Cancers
TARGET PARTNERS
Who Is This Initiative For?
Designed for healthcare institutions and professionals at the forefront of cancer treatment.
Oncology Hospitals
Comprehensive cancer centers seeking advanced radiopharmaceutical solutions.
Nuclear Medicine Department
Hospital departments specializing in diagnostic and therapeutic nuclear procedures.
Research Institutions
Academic and clinical research facilities advancing cancer treatment protocols.
Radiation Oncologists
Specialists requiring reliable radioisotope supply for patient treatment.
Join Us in Transforming Cancer Care
Express your interest in partnering with Saturn Group as we embark on this groundbreaking initiative to bring advanced radioisotope therapy to India.